TD Cowen analyst Ritu Baral reiterated a Buy rating and $45.00 price target on Insmed (NASDAQ: INSM).The analyst commented, "This ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Insmed (INSM) PT Raised to $67 at StifelMay 30, 2024 4:35 PM Insmed (INSM) PT Raised to $58 at UBSMay 29, 2024 5:37 AM Insmed (INSM) PT Raised to $68 at Truist SecuritiesMay 29, 2024 5:30 AM Insmed (INSM) PT Raised to $54 at Wolfe ResearchMay 29, 2024 5:25 AM Insmed (INSM) PT Raised to $62 at BofA SecuritiesMay 29, 2024 5:08 AM Insmed (INSM) PT Raised to $60 at Morgan StanleyMay 28, 2024 2:37 PM Goldman Sachs Reiterates Buy Rating on Insmed (INSM)May 28, 2024 1:27 PM